Arguments in favour of remdesivir for treating SARS-CoV-2 infections.Int J Antimicrob Agents. 2020 Apr; 55(4):105933.IJ
Links
MeSH
Pub Type(s)
Editorial
Language
eng
PubMed ID
32147516
Clinical Trial Links
Citation
Ko, Wen-Chien, et al. "Arguments in Favour of Remdesivir for Treating SARS-CoV-2 Infections." International Journal of Antimicrobial Agents, vol. 55, no. 4, 2020, p. 105933.
Ko WC, Rolain JM, Lee NY, et al. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents. 2020;55(4):105933.
Ko, W. C., Rolain, J. M., Lee, N. Y., Chen, P. L., Huang, C. T., Lee, P. I., & Hsueh, P. R. (2020). Arguments in favour of remdesivir for treating SARS-CoV-2 infections. International Journal of Antimicrobial Agents, 55(4), 105933. https://doi.org/10.1016/j.ijantimicag.2020.105933
Ko WC, et al. Arguments in Favour of Remdesivir for Treating SARS-CoV-2 Infections. Int J Antimicrob Agents. 2020;55(4):105933. PubMed PMID: 32147516.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
AU - Ko,Wen-Chien,
AU - Rolain,Jean-Marc,
AU - Lee,Nan-Yao,
AU - Chen,Po-Lin,
AU - Huang,Ching-Tai,
AU - Lee,Ping-Ing,
AU - Hsueh,Po-Ren,
Y1 - 2020/03/06/
PY - 2020/2/16/received
PY - 2020/2/28/revised
PY - 2020/3/10/pubmed
PY - 2020/4/30/medline
PY - 2020/3/10/entrez
KW - Betacoronavirus
KW - COVID-19
KW - Coronavirus disease 2019
KW - Remdesivir
KW - SARS-CoV-2
KW - Wuhan pneumonia
SP - 105933
EP - 105933
JF - International journal of antimicrobial agents
JO - Int J Antimicrob Agents
VL - 55
IS - 4
SN - 1872-7913
UR - https://www.unboundmedicine.com/medline/citation/32147516/Arguments_in_favour_of_remdesivir_for_treating_SARS_CoV_2_infections_
DB - PRIME
DP - Unbound Medicine
ER -